Acknowledgements
Barrett, Cancer
BARRETT, CANCER
The authors would like to acknowledge the input from the following people: Ed Ainscow, Anthony Barrett, Paul Dickinson, Iain Macpherson, Kristine Pemberton and Manfred Lehnert. The study was designed and funded by Carrick Therapeutics. Carrick Therapeutics also provided funding to third party Contract Research Organisations for data collection and processing. Debbie Jordan Ltd provided medical writing services for this manuscript, with the cost of these services paid by Carrick Therapeutics. R.C.C. and S.A. would like to acknowledge Cancer Research UK for funding (C37/A18784). M.G.K. and S.H. acknowledge support from National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, NIHR Manchester Clinical Research Facility at The Christie and Manchester Experimental Cancer Medicine Centre (Manchester, UK). S.R.L. acknowledges support from The Oxford Experimental Cancer Medicine Centre and National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. L.K. acknowledges infrastructure support from the Imperial Experimental Cancer Medicine Centre, Cancer Research UK Imperial Centre, National Institute for Health Research (NIHR), Imperial Biomedical Research Centre (BRC), Imperial College Healthcare NHS Trust Tissue Bank, and the NIHR Imperial Clinical Research Facility. C.P. acknowledges support from The Liverpool Experimental Cancer Medicine Centre [Grant Reference: C18616/A25153], Cancer Research UK. R.B. acknowledges support from the Cancer Research UK Cambridge Centre, Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre including Cambridge Clinical Research Centre (grant #BRC-1215-20014). The views expressed in this paper are those of the authors and not necessarily those of the supporting bodies listed above.